Baxter-Holland, M., & Dass, C. (2018). Doxorubicin, mesenchymal stem cell toxicity and antitumour activity: Implications for clinical use. John Wiley & Sons Ltd.
Chicago Style (17th ed.) CitationBaxter-Holland, M., and Crispin Dass. Doxorubicin, Mesenchymal Stem Cell Toxicity and Antitumour Activity: Implications for Clinical Use. John Wiley & Sons Ltd, 2018.
MLA (9th ed.) CitationBaxter-Holland, M., and Crispin Dass. Doxorubicin, Mesenchymal Stem Cell Toxicity and Antitumour Activity: Implications for Clinical Use. John Wiley & Sons Ltd, 2018.
Warning: These citations may not always be 100% accurate.